IL1RAP
ENSG00000196083
Target class
Enzyme
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- IL1RAP
- Gene name
- Interleukin 1 receptor accessory protein
- Gene symbol
- IL1RAP
- Protein name
- Interleukin-1 receptor accessory protein (IL-1 receptor accessory protein) (IL-1RAcP) (EC 3.2.2.6) (Interleukin-1 receptor 3) (IL-1R-3) (IL-1R3)
- IL-1RAcP
- IL1R3
- C3orf13
- Gene biotype
- Protein coding
- Gene family
- Immunoglobulin like domain containing|Interleukin receptors|TIR domain containing
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 42
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 13.57
- Tissue specificity (Gini)
- 0.46
- Tissue specificity (tau)
- 0.826
- KEGG gene identifiers
- hsa:3556
- Protein interaction confidence
- 0.917864
- Protein interaction partners
- 22
- End position
- 190659750
- Start position
- 190514051
- Chromosome
- 3
- Strand
- Forward
- [Isoform 1]: Cell membrane
- Single-pass type I membrane protein.
- SUBCELLULAR LOCATION: [Isoform 2]: Secreted.
- SUBCELLULAR LOCATION: [Isoform 3]: Secreted.
- Cytosol
- Vesicles
- Tissue specificity (tau)
- 0.826268
- Expression inequality (Gini)
- 0.460348
Expression in transcripts per million
- Liver
- 13.57
- Whole Blood
- 9.54
- Esophagus - Mucosa
- 7.83
- Lung
- 7.24
- Skin - Not Sun Exposed (Suprapubic)
- 6.96
Expression in transcripts per million
- Liver13.57
- Whole Blood9.54
- Esophagus - Mucosa7.83
- Lung7.24
- Skin - Not Sun Exposed (Suprapubic)6.96
- Skin - Sun Exposed (Lower leg)6.5
- Cells - Cultured fibroblasts5.3
- Vagina5.1
- Fallopian Tube4.06
- Minor Salivary Gland3.47
- Artery - Coronary3.24
- Nerve - Tibial3.17
- Uterus3.05
- Adipose - Visceral (Omentum)3.03
- Spleen3.02
- Artery - Tibial2.77
- Breast - Mammary Tissue2.52
- Artery - Aorta2.45
- Bladder2.38
- Adipose - Subcutaneous2.35
- Prostate2.17
- Cervix - Ectocervix2.17
- Cervix - Endocervix2.16
- Brain - Frontal Cortex (BA9)1.95
- Ovary1.87
And 29 more, listed on the interactive page.
- GO:0006954
- GO:0006955
- GO:0038172
- GO:0043123
- GO:0043410
- GO:0065003
- GO:0070498
- GO:0005886
- GO:0016020
- GO:0005515
- GO:0015026
Related records
Trials (51)
- A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.
- A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated
- A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy
- A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial
- A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease
- A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
- A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash
- A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects
- A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
- A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
- A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
- A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa
- A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
- A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps
- A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
Drugs (3)
- Astegolimab IL-33 receptor (ST2) inhibitor
- Imsidolimab IL36 receptor antagonist
- Spesolimab IL36 receptor antagonist